2024 ESMO Asia | 超40项中国口头报告披露，中国之声汇聚全球目光|单抗|讲者|治疗|asia|nsclc

分享至

前言

2024年欧洲肿瘤内科学会亚洲年会（ESMO ASIA）将于当地时间12月6日~8日在新加坡召开。ESMO ASIA是亚太地区讨论肿瘤学领域重磅突破的领先平台，届时将公布多项全球及亚太地区的最新科研和临床进展。目前大会官网已披露了摘要标题，本届大会中多项中国研究入选口头报告，医脉通特整理如下，让我们一睹为快吧。

胸部恶性肿瘤

摘要号：LBA6

PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)

PACIFIC-5研究：度伐利尤单抗作为巩固治疗在同步或序贯放化疗后未进展的不可切除III期NSCLC患者中的有效性和安全性

讲者：吴一龙广东省人民医院

摘要号：625O

Efficacy and safety of Lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: a randomized, double-blind, placebo-controlled multicenter phase II trial

Lucitanib (AL3810) 在晚期复发性或转移性胸腺癌二线或后续治疗中的疗效和安全性：一项随机、双盲、安慰剂对照的多中心II期试验

讲者：方文涛上海交通大学医学院附属胸科医院

摘要号：627MO

POD1UM-304: Phase 3 Study of Retifanlimab Plus Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Therapy For Nonsquamous or Squamous Metastatic Non–Small Cell Lung Cancer (mNSCLC)

POD1UM-304：Retifanlimab联合铂类化疗作为非鳞状或鳞状转移性NSCLC一线治疗的III期研究

讲者：陆舜上海交通大学医学院附属胸科医院

摘要号：614MO

A Phase Ⅱ Study of Becotatug (JMT101) in Combination with Osimertinib (Osi) in Patients (pts) with classical EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (BOOSTER Study)

Becotatug(JMT101)联合奥希替尼治疗经典型EGFR突变NSCLC的Ⅱ期临床研究(BOOSTER研究)

讲者：张力中山大学肿瘤防治中心

摘要号：629MO

ALESIA 7-year update: alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC)

ALESIA研究7年更新：阿来替尼对比克唑替尼治疗初治的晚期ALK+NSCLC亚洲患者

讲者：周彩存同济大学附属东方医院

乳腺癌

摘要号：2O

Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2− early breast cancer (EBC)

NATALEE研究亚洲和非亚洲患者分析：瑞波西利+非甾体芳香化酶抑制剂治疗HR+/HER2−早期乳腺癌

讲者：徐兵河中国医学科学院肿瘤医院

摘要号：27O

Assessment of overall survival benefit from neoadjuvant chemotherapy in elderly HER-2 negative LN+ breast cancer patients: A population-based study

评估老年HER2-/LN+乳腺癌患者新辅助化疗的总体生存获益：一项基于人群的研究

讲者：吕文杰上海交通大学医学院附属新华医院

摘要号：36O

18F-fluoroestradiol (18F-FES) PET/CT guided first-line treatment for HR+/HER2- metastatic breast cancer patients: Experience from real-world

18F-氟雌二醇(18F-FES)PET/CT引导下的HR+/HER2-转移性乳腺癌患者一线治疗：来自真实世界的经验

讲者：王碧芸复旦大学附属肿瘤医院

摘要号：37MO

HER2-low heterogeneity and its impact on benefit from Trastuzumab Deruxtecan in metastatic breast cancer

HER2低异质性及其对转移性乳腺癌患者T-DXd治疗获益的影响

讲者：邹宇田中山大学肿瘤防治中心

摘要号：38MO

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Results from TROPION-Breast01 China cohort

Dato-DXd对比化疗治疗经治的不可手术/转移性HR+/HER2–乳腺癌：TROPION-Breast01研究中国队列结果

讲者：王树森中山大学肿瘤防治中心

摘要号：28MO

Dynamic evolution of vascular features based on magnetic resonance imaging to predict pathological response and survival outcomes in breast cancer patients undergoing neoadjuvant chemotherapy

基于磁共振成像的血管特征动态演变预测接受新辅助化疗的乳腺癌患者的病理反应和生存结果

讲者：吴琼上海交通大学医学院附属仁济医院

胃肠道肿瘤

摘要号：126O

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis

纳武利尤单抗联合伊匹木单抗对比仑伐替尼或索拉非尼作为不可切除性肝细胞癌一线治疗：CheckMate 9DW亚洲亚组分析

讲者：Thomas Yau 香港大学

摘要号：129MO

Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive (HER2+) advanced gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric06 (DG-06) final analysis

T-DXd治疗中国HER2+晚期胃腺癌或胃食管交界处腺癌患者：DESTINY-Gastric06(DG-06)最终分析

讲者：彭智北京大学肿瘤医院

摘要号：132MO

Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): updated results from a phase 1 study

抗claudin18.2(CLDN18.2) ADC IBI343治疗晚期胰腺导管腺癌(PDAC)患者：I期研究结果

讲者：虞先濬复旦大学附属肿瘤医院

摘要号：74MO

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in Locally Advanced MSS CRC (BASKETⅡ): A Prospective, Single-Arm, Open-Label, Phase II Study

mFOLFOX6+贝伐珠单抗+PD-1抗体治疗局部晚期MSS CRC(BASKETⅡ)：一项前瞻性、单臂、开放标签、II期研究

讲者：黄俊中山大学附属第六医院

妇科肿瘤

摘要号：372O

Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: An open-label, non-comparative, randomised, phase II trial

单独使用Balstilimab或与zalifrelimab联合治疗宫颈癌：一项开放标签、非对比、随机、II期试验

讲者：吴令英中国医学科学院肿瘤医院

摘要号：373O

First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study

一线iparomlimab和tuvonralimab(QL1706)+化疗±贝伐珠单抗治疗复发或转移性宫颈癌(r/mCC)：II期DUBHE-C-204研究最新结果

讲者：王丹波辽宁省肿瘤医院

摘要号：374O

The burden and trends of gynecological cancers in Asia from 1980 to 2021: A systematic analysis for the Global Burden of Disease Study 2021

1980年至2021年亚洲妇科肿瘤负担及趋势：2021年全球疾病负担研究的系统分析

讲者：Run Miao 安徽医科大学

摘要号：376MO

The impact of crossover to surgery in the no-surgery group on the survival: a post-hoc analysis of the SOC-1 trial

非手术组交叉手术对生存的影响：SOC-1试验的事后分析

讲者：Lina Shen 上海

摘要号：377MO

Lymph node dissection before initial treatment for locally advanced cervical cancer: A systematic review and meta-analysis

局部晚期宫颈癌初始治疗前应用淋巴结清扫术：系统评价和荟萃分析

讲者：He Zhang 中国医学科学院肿瘤医院

摘要号：378MO

Efficacy and Safety of Disitamab Vedotin in Treatment of HER2 Expressed Advanced or Recurrent Gynecological Cancers

维迪西妥单抗治疗HER2表达的晚期或复发性妇科肿瘤的疗效和安全性

讲者：王东雁中山大学孙逸仙纪念医院

泌尿生殖系统肿瘤

摘要号：268O

Serum amyloid a promotes resistance to neoadjuvant toripalimab plus axitinib in renal cell carcinoma with venous tumor thrombus

血清淀粉样蛋白a可促进伴有静脉癌栓的肾细胞癌对新辅助特瑞普利单抗联合阿昔替尼治疗产生耐药性

讲者：顾良友中国人民解放军总医院

摘要号：336MO

A phase II single-arm, open-label trial of Pamiparib in metastatic castration-resistant prostate cancer (mCRPC) patients with deleterious germline or Somatic BRCA1/2 alterations or homologous recombination deficiency (HRD): Interim analysis of efficacy and safety results

帕米帕利治疗携带有害胚系或体细胞BRCA1/2突变或同源重组缺陷(HRD)的转移性去势抵抗性前列腺癌(mCRPC)患者的II期单臂、开放性试验：疗效和安全性结果的期中分析

讲者：Diwei Zhao 中山大学肿瘤防治中心

摘要号：337MO

Efficacy and safety of rezvilutamide (Rez) plus androgen-deprivation therapy (ADT) in patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) aged ≤64, 65–74, and ≥75 years: Post-hoc analysis of randomized phase 3 CHART trial

瑞维鲁胺联合雄激素剥夺疗法在年龄≤64岁、65–74岁和≥75岁的高瘤负荷转移性激素敏感性前列腺癌(mHSPC)患者中的疗效和安全性：随机化III期CHART试验的事后分析

讲者：叶定伟复旦大学附属肿瘤医院

摘要号：272MO

PUNCH01: Interim results from a phase II study of intraarterial chemotherapy (IAC) combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)

PUNCH01：动脉化疗(IAC)联合替雷利珠单抗和卡介苗治疗高风险非肌层浸润性膀胱癌(HR NMIBC)的II期研究中期结果

讲者：王宗任中山大学附属第一医院

摘要号：274MO

Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial

呋喹替尼联合斯鲁利单抗作为晚期非透明细胞肾细胞癌(nccRCC)一线治疗的疗效和安全性：一项单臂、多中心临床试验

讲者：黄吉炜上海交通大学医学院附属仁济医院

摘要号：338MO

Efficacy and safety of Tislelizumab(T) combined with Gemcitabine and Cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, r (la/mUC) inphase II study

局部肌层浸润性膀胱癌(MIBC)患者根治性局部手术后接受替雷利珠单抗联合吉西他滨和顺铂治疗的疗效和安全性：一项前瞻性II期研究

讲者：曹明上海交通大学医学院附属仁济医院

摘要号：276MO

Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cance Taiwan: A retrospective cohort study

台湾局部晚期或转移性尿路上皮癌(la/mUC)患者的流行病学、治疗模式和临床结果：一项回顾性队列研究

讲者：Chun-Te Wu 台湾长庚纪念医院

头颈肿瘤

摘要号：LBA3

First-line HLX07 vs. Placebo Combined with Serplulimab and Chemotherapy for Nasopharyngeal Cancer: a Randomised, Double-blind, Multicentre Phase 2 study

HLX07对比安慰剂联合斯鲁利单抗和化疗一线治疗鼻咽癌：一项随机、双盲、多中心II期临床研究

讲者：张力中山大学肿瘤防治中心

摘要号：402O

Preliminary results of phase II study to evaluate safety and efficacy of combination Pucotenlimab with Epidermal Growth Factor Receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)

Pucotenlimab联合EGFR-ADC MRG003治疗复发或转移性鼻咽癌(R/M-NPC)的安全性和有效性的II期研究的初步结果

讲者：徐瑞华中山大学肿瘤防治中心

摘要号：403O

Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study

替雷利珠单抗联合化疗对比安慰剂联合化疗作为复发性或转移性鼻咽癌一线治疗：RATIONALE-309研究的III年随访结果

讲者：方文峰中山大学肿瘤防治中心

摘要号：407MO

Capecitabine combined with PD-1 antibody as maintenance therapy after first-line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score matching study

卡培他滨联合PD-1抗体作为复发或转移性鼻咽癌一线治疗后的维持治疗：倾向评分匹配研究

讲者：Yifu Li 中山大学肿瘤防治中心

摘要号：408MO

Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

确定局部晚期鼻咽癌同步放化疗后开始辅助化疗的最佳时机

讲者：Hui Cheng 中山大学肿瘤防治中心

摘要号：409MO

Induction chemo-immunotherapy with camrelizumab plus modified TPF (nab-paclitaxel, cisplatin, and S1) in locally advanced nasopharyngeal carcinoma: A phase II, single-arm study

局部晚期鼻咽癌患者应用卡瑞利珠单抗联合改良TPF(白蛋白结合型紫杉醇、顺铂和S1)进行诱导化学免疫治疗：一项II期单臂研究

讲者：吴三纲厦门大学附属第一医院

摘要号：410MO

Pattern and treatment outcomes of second primary cancer (SPC) of the upper aerodigestive tract (UADT) in head and neck squamous cell carcinoma (HNSCC) survivors: A multi-center retrospective cohort study with long-term follow-up

头颈部鳞癌(HNSCC)幸存者上呼吸消化道(UADT)第二原发癌(SPC)的模式和治疗结果：一项长期随访的多中心回顾性队列研究

讲者：Chak Ki J. Yung 香港伊丽莎白医院

发展与精准医学

摘要号：57O

A phase 1/2 multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors

DB-1311/BNT324(新型B7H3 ADC)治疗晚期实体瘤患者的I/II期多中心首次人体研究结果

讲者：程颖吉林省肿瘤医院

摘要号：58O

Clinical efficacy, safety, and PK/PD from the first in human study of BM201, a TLR7/8 agonist

BM201(TLR7/8激动剂)首次人体研究的临床疗效、安全性和PK/PD结果

讲者：李茹恬南京鼓楼医院

摘要号：478O

Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients (pts) from a Phase 1 Study

口服PD-L1抑制剂ABSK043治疗晚期实体瘤的I期研究最新结果

讲者：虞永峰上海交通大学医学院附属胸科医院

摘要号：59O

A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma

新型小分子PD-L1抑制剂BPI-371153在晚期实体瘤或复发/难治性淋巴瘤中的首次人体I期研究结果

讲者：杨建良中国医学科学院北京协和医学院

摘要号：61O

Updated results of a phase II trial evaluating an Anti-EpCAM x Anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites

抗EpCAMx抗CD3双特异性抗体M701治疗恶性腹水的II期试验的最新结果

讲者：刘容锐中国人民解放军总医院

支持和姑息治疗

摘要号：528MO

Cognitive phenotypes and its association with role functioning outcomes in adolescents and young adults (AYAs) with cancer

青少年和青年癌症患者的认知表型及其与角色功能结果的关联

讲者：Panpan Xiao 香港中文大学

青年医生临床病例讨论

摘要号：YO27

Negative Predicting Value of Longitudinal Undetectable MRD in Maintenance Immunotherapy for Advanced Lung Cancer Patients: A Case Report

晚期肺癌患者维持免疫治疗中纵向不可检测MRD的阴性预测值：病例报告

讲者：Xiran He 首都医科大学附属北京胸科医院

摘要号：YO29

Multiple primary cancers (MPC) of breast and lung with primary EGFR T790M mutation Responded to Aumolertinib: A case report

携带原发性EGFR T790M突变的乳腺癌和肺癌多发性原发癌(MPC)对阿美替尼治疗有效：病例报告

讲者：Shengnan Kong 空军军医大学西京医院

摘要号：YO1

Trastuzumab deruxtecan and Stereotactic radiosurgery (SRS) in HER2-positive (HER2+) breast cancer with brain metastases (BM)

T-DXd联合立体定向放射外科(SRS)治疗HER2+乳腺癌脑转移(BM)

讲者：Teng Meng 陆军特色医学中心(大坪医院)

编辑：Faline

审校：Faline

排版：Faline

执行：Squid

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。

Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.